Matches in SemOpenAlex for { <https://semopenalex.org/work/W2144057039> ?p ?o ?g. }
Showing items 1 to 63 of
63
with 100 items per page.
- W2144057039 endingPage "A345" @default.
- W2144057039 startingPage "A345" @default.
- W2144057039 abstract "To assess the cost-effectiveness of pegylated interferons alfa-2a and alfa-2b combined with ribavirin in the treatment of Russian patients with chronic hepatitis C and identify potential budget impact considering the indicator of rational drug use (IRDU). The pharmacoeconomic model was developed based on the data from randomized controlled trial MIST (M. Rumi et al., 2010). The cost-effectiveness ratios (CERs) for different patient subgroups were expressed as costs of medicines per one patient with sustained virologic response. 24- and 48-week time frames were used for patients with genotypes 2/3 and 1/4, respectively. To assess quantitatively the impact of pharmaceutical form and recommended dose regimens, the IRDU was used. One-way sensitivity analyses (SAs) were performed to investigate the robustness of the cost-effectiveness estimates. Treatment with pegylated interferon alfa-2a was associated with lower total costs. The estimated budget savings varied from 20,907.97 RUB to 104,366.07 RUB per one patient. CERs for pegylated interferon alfa-2a were less than that for pegylated interferon alfa-2b in all patient subgroups. The lowest CER was observed for patients with genotype 2 received pegylated interferon alfa-2a (240,789.70 RUB per one patient with SVR) and the highest CER – for cirrhotic patients with genotype 1 received pegylated interferon alfa-2b (1,879,694.72 RUB per one patient with SVR). The analysis of the IRDU showed, that inefficient budget expenses associated with pegylated interferon alfa-2b treatment may reach 58,770.84 RUB per one patient infected with HCV-genotypes 1/4. SAs demonstrated that results were robust to changes in the drug costs. The present study has demonstrated that administration of pegylated interferon alfa-2a has the better pharmacoeconomic profile in the treatment of Russian patients with chronic hepatitis C." @default.
- W2144057039 created "2016-06-24" @default.
- W2144057039 creator A5060288149 @default.
- W2144057039 creator A5060534806 @default.
- W2144057039 creator A5080622925 @default.
- W2144057039 date "2013-11-01" @default.
- W2144057039 modified "2023-09-30" @default.
- W2144057039 title "Pharmacoeconomic Analysis of Different Antiviral Therapies in the Treatment of Russian Patients with Chronic Hepatitis C" @default.
- W2144057039 doi "https://doi.org/10.1016/j.jval.2013.08.136" @default.
- W2144057039 hasPublicationYear "2013" @default.
- W2144057039 type Work @default.
- W2144057039 sameAs 2144057039 @default.
- W2144057039 citedByCount "0" @default.
- W2144057039 crossrefType "journal-article" @default.
- W2144057039 hasAuthorship W2144057039A5060288149 @default.
- W2144057039 hasAuthorship W2144057039A5060534806 @default.
- W2144057039 hasAuthorship W2144057039A5080622925 @default.
- W2144057039 hasBestOaLocation W21440570391 @default.
- W2144057039 hasConcept C126322002 @default.
- W2144057039 hasConcept C203014093 @default.
- W2144057039 hasConcept C2522874641 @default.
- W2144057039 hasConcept C2776178377 @default.
- W2144057039 hasConcept C2776455275 @default.
- W2144057039 hasConcept C2776461080 @default.
- W2144057039 hasConcept C2780040827 @default.
- W2144057039 hasConcept C2781228144 @default.
- W2144057039 hasConcept C2909179924 @default.
- W2144057039 hasConcept C3020491458 @default.
- W2144057039 hasConcept C71924100 @default.
- W2144057039 hasConcept C90924648 @default.
- W2144057039 hasConceptScore W2144057039C126322002 @default.
- W2144057039 hasConceptScore W2144057039C203014093 @default.
- W2144057039 hasConceptScore W2144057039C2522874641 @default.
- W2144057039 hasConceptScore W2144057039C2776178377 @default.
- W2144057039 hasConceptScore W2144057039C2776455275 @default.
- W2144057039 hasConceptScore W2144057039C2776461080 @default.
- W2144057039 hasConceptScore W2144057039C2780040827 @default.
- W2144057039 hasConceptScore W2144057039C2781228144 @default.
- W2144057039 hasConceptScore W2144057039C2909179924 @default.
- W2144057039 hasConceptScore W2144057039C3020491458 @default.
- W2144057039 hasConceptScore W2144057039C71924100 @default.
- W2144057039 hasConceptScore W2144057039C90924648 @default.
- W2144057039 hasIssue "7" @default.
- W2144057039 hasLocation W21440570391 @default.
- W2144057039 hasOpenAccess W2144057039 @default.
- W2144057039 hasPrimaryLocation W21440570391 @default.
- W2144057039 hasRelatedWork W1978167988 @default.
- W2144057039 hasRelatedWork W1985882441 @default.
- W2144057039 hasRelatedWork W2014171438 @default.
- W2144057039 hasRelatedWork W2070354233 @default.
- W2144057039 hasRelatedWork W2076626959 @default.
- W2144057039 hasRelatedWork W2124098035 @default.
- W2144057039 hasRelatedWork W2317554121 @default.
- W2144057039 hasRelatedWork W2411773677 @default.
- W2144057039 hasRelatedWork W2461318346 @default.
- W2144057039 hasRelatedWork W2462498398 @default.
- W2144057039 hasVolume "16" @default.
- W2144057039 isParatext "false" @default.
- W2144057039 isRetracted "false" @default.
- W2144057039 magId "2144057039" @default.
- W2144057039 workType "article" @default.